This application constitutes a renewal on the part of the University of California/Los Angeles (UCLA) for a Center for AIDS Research (CFAR) grant. This grant will fund activities and programs conducted by the UCLA AIDS Institute. The UCLA AIDS Institute was established in 1992 to coordinate all AIDS research, clinical and educational activities at the University and its seven affiliated teaching hospitals under one central administration. Dr. S.Y. Chen was appointed the founding and current Director of the AIDS Institute and is also the Principal Investigator of the UCLA CFAR. This renewal application includes core services and activities described herein that are designed to advance knowledge of HIV/AIDS through the basic, clinical, and behavioral sciences. The overall goal is to develop therapies and approaches to prevent and ultimately eliminate the threat of HIV/AIDS. The Institute consists of more than 150 faculty investigators responsible for over 200 research projects that encompass various aspects of HIV/AIDS biology, clinical studies, and behavioral science investigations. UCLA has consistently been ranked among the top five institutions by various sources for its excellence in AIDS research, education and teaching, and clinical programs. Metropolitan Los Angeles is a major epicenter for the AIDS epidemic and one of the most culturally diverse regions in the nation. The role of the Institute is to foster collaboration and build linkages both within and outside the university. Its emphasis is on the development of innovate approaches through the formation of multidisciplinary collaborations and provision of key technologies through core facilities to all AIDS researchers in UCLA. Additionally, the Institute is proactive in providing an """"""""investigator friendly"""""""" environment to external research efforts that fall within the scope of its aims and goals. Alliances are supported through symposia, informal Think Tanks and seed grants. The Institute also works to identify and recruit new faculty investigators whose background and experience will strengthen research programs that the Institute has determine to be underrepresented, and/or timely. The action plan for the first year of requested support, January 1998 through December 1998, is summarized as follows. The Institute plans to continue supporting the seven cores originally funded by the previous CFAR, Administrative Core, Developmental Core, Virology/BSL3 Tissue Culture Core, Flow Cytometry/Cell Sorting Core, Mouse/Human Chimera Core, Clinical Investigations Core, and Gene and Cellular Therapy Core. In addition, through additional support through the CFAR, the Institute requests ongoing support for two cores, initiated through finds made available be private fund-raising efforts, the Mucosal Immunology Core and Biostatistics Core. Finally, the Institute requests support for three new cores, an International Core, and two behavioral science cores, and Adherence to HIV Medication Core, and a Behavioral Adherence, Recruitment and Retention Core, which together comprise the Health Behavior and Outreach Program.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI028697-12
Application #
6373172
Study Section
Special Emphasis Panel (ZAI1-SCO-A (J1))
Program Officer
Young, Janet M
Project Start
1991-09-01
Project End
2003-06-30
Budget Start
2001-07-01
Budget End
2002-06-30
Support Year
12
Fiscal Year
2001
Total Cost
$1,512,031
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Beymer, Matthew R; Kofron, Ryan M; Tseng, Chi-Hong et al. (2018) Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County. Int J STD AIDS 29:557-562
Swendeman, Dallas; Fehrenbacher, Anne E; Roy, Soma et al. (2018) Gender disparities in depression severity and coping among people living with HIV/AIDS in Kolkata, India. PLoS One 13:e0207055
Ramos, Juan C; Sparano, Joseph A; Rudek, Michelle A et al. (2018) Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). Clin Lymphoma Myeloma Leuk 18:180-190.e2
Matassoli, Flávio Lemos; Leão, Ihid Carneiro; Bezerra, Bruno Braz et al. (2018) Hydroxypropyl-Beta-Cyclodextrin Reduces Inflammatory Signaling from Monocytes: Possible Implications for Suppression of HIV Chronic Immune Activation. mSphere 3:
Woo, Jin Seok; Srikanth, Sonal; Kim, Kyun-Do et al. (2018) CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses. J Immunol 201:1174-1185
Jia, Qingmei; Bowen, Richard; Dillon, Barbara Jane et al. (2018) Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci Rep 8:7009
Arfer, Kodi B; Tomlinson, Mark; Mayekiso, Andile et al. (2018) Criterion validity of self-reports of alcohol, cannabis, and methamphetamine use among young men in Cape Town, South Africa. Int J Ment Health Addict 16:45-52
Van, Christina; Condro, Michael C; Lov, Kenny et al. (2018) PACAP/PAC1 Regulation of Inflammation via Catecholaminergic Neurons in a Model of Multiple Sclerosis. J Mol Neurosci :
Shannon, Chelsea Lee; Bristow, Claire; Hoff, Nicole et al. (2018) Acceptability and Feasibility of Rapid Chlamydial, Gonococcal, and Trichomonal Screening and Treatment in Pregnant Women in 6 Low- to Middle-Income Countries. Sex Transm Dis 45:673-676
Furler, Robert L; Nixon, Douglas F; Brantner, Christine A et al. (2018) TGF-? Sustains Tumor Progression through Biochemical and Mechanical Signal Transduction. Cancers (Basel) 10:

Showing the most recent 10 out of 942 publications